picropodophyllin has been researched along with Benign Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Benham, V; Bernard, JJ; Bernard, MP; Bullard, B; Dexheimer, TS; Liby, KT; Neubig, RR | 1 |
| Axelson, M; Fryknäs, M; Girnita, L; Hashemi, J; Jernberg-Wiklund, H; Karimi, M; Larsson, C; Larsson, O; Lui, WO; Rudduck, C; Sulaiman, L; Vasilcanu, D; Weng, WH; Worrall, C | 1 |
| Axelson, M; Girnita, A; Girnita, L; Larsson, C; Larsson, O; Lui, WO; Vasilcanu, D; Vasilcanu, R; Weng, WH | 1 |
| Axelson, M; Girnita, A; Girnita, L; Larsson, O; Natalishvili, N; Rosengren, L; Sehat, B; Vasilcanu, D; Vasilcanu, R; Yin, S | 1 |
1 review(s) available for picropodophyllin and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
4 other study(ies) available for picropodophyllin and Benign Neoplasms
| Article | Year |
|---|---|
Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay.
Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cell Proliferation; Cell Transformation, Neoplastic; Drug Screening Assays, Antitumor; Fibroblast Growth Factor 2; Fibroblasts; Fluvastatin; High-Throughput Screening Assays; Humans; Mice; Models, Biological; Neoplasms; Obesity; Podophyllotoxin; Skin | 2019 |
Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP).
Topics: Allelic Imbalance; Cell Line, Tumor; Chromosome Aberrations; Cluster Analysis; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genotype; Humans; In Situ Hybridization, Fluorescence; Metaphase; Neoplasms; Podophyllotoxin; Proto-Oncogene Proteins c-myc; Reproducibility of Results; RNA, Small Interfering; Spectral Karyotyping | 2011 |
The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Multidrug Resistance-Associated Proteins; Neoplasms; Phosphorylation; Podophyllotoxin; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2006 |
Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1.
Topics: Animals; Aorta; Apoptosis; Arrestins; beta-Arrestins; Blotting, Western; Cell Proliferation; Cells, Cultured; Down-Regulation; Flow Cytometry; Humans; Immunoprecipitation; Insulin-Like Growth Factor I; Mice; Neoplasms; Podophyllotoxin; Proto-Oncogene Proteins c-mdm2; Receptor, IGF Type 1; Receptor, Insulin; Swine; Ubiquitin | 2008 |